Calcipotriol

• (5Z, 7E, 22E, 24S ) -24 -cyclopropyl- 9 ,10- secochola -5, 7,10 (19) ,22- tetraene - 1α, 3β ,24 -triol (IUPAC)
• Calcipotriene ( USAN )

D05AX02

Risk

2.19 mg · kg -1 ( LD50, rat, s.c )

Template: Infobox chemical / molecular formula search available

Calcipotriol is a man-made chemical compound from the group of secosteroids. It is used in medicine as a drug for the topical treatment of psoriasis ( psoriasis). Calcipotriol is an analogue of cholecalciferol (vitamin D3).

• 2.1 Combination Therapy 2.1.1 calcipotriol and betamethasone
• 2.1.2 Other combinations

Clinical information

Areas of application (indications )

Externally to treat psoriasis ( psoriasis), normalizes the cell growth and division rate of skin cells.

Contraindications ( contraindications)

Diseases with changes in calcium metabolism, severe liver and kidney disease.

Use during pregnancy and lactation

Treatment during pregnancy and lactation should be avoided as there is no experience.

Adverse effects (side effects)

Skin irritation (redness, itching, burning)

Mechanism of action ( pharmacodynamics )

The effect is mediated by the Vitamin D receptor. Vitamin D3 analogs suppress the production of pro- inflammatory cytokines that play a role in psoriatic inflammatory process and induce the formation of anti-inflammatory cytokines acting. Furthermore, the vitamin D3 signaling interfering with other transcription factors, which are considered important for the increased production of inflammatory mediators in psoriasis vulgaris. A main part of the anti-psoriatic effect is likely to be that which inhibits keratinocyte proliferation and the degree of differentiation is increased.

Other Information

Combination therapy

Calcipotriol and betamethasone

A fixed combination with corticosteroids is especially useful at the beginning of psoriasis treatment, since a faster onset of action can be achieved and at the same time possible cutaneous irritation are suppressed. The only once-daily therapy with the fixed combination of calcipotriol / betamethasone has a very good practicability and high compatibility. The guideline for medical treatment of scalp psoriasis this fixed-dose combination is recommended as initial therapy.

Other combinations

Note the risk of impact attenuation with concomitant administration of salicylate keratolytic or dithranol preparations, as well as a possible increase in local irritating effects in combination with vitamin A derivatives ( tazarotene ). Drug Interactions: Concomitant systemic use of calcium or vitamin D3 in serum calcium levels should be monitored regularly, as well as for medicinal products that may increase serum calcium levels. Treatment recommendation: When local therapy, particularly maintenance therapy in mild to moderate psoriasis vulgaris, the vitamin D3 derivatives drug of first choice. In the first weeks of treatment, a combination with topical corticosteroids is superior as a fixed combination of efficacy and tolerability of monotherapy.

History

In 1992, the first vitamin D3 analogue calcipotriol for the topical treatment of mild to moderate psoriasis vulgaris was allowed. 2002, the approval of the fixed combination product calcipotriol / betamethasone for the initial treatment of psoriasis vulgaris was made.